(Sharecast News) - Shore Capital downgraded drugmaker AstraZeneca from 'buy' to 'hold' on Friday, stating the drugmaker's near‑term earnings outlook looked less favourable despite what it called "exceptional" R&D delivery.
The broker said AstraZeneca's 16 positive readouts in 2025, and more than 20 expected in 2026, supported confidence in its ambition...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE